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Abstract
Background: Asthma is one of the most common chronic diseases and a major economical
burden to families and health systems. Whereas efficacy of current therapeutical options has been
clearly established, cost-effectiveness analysis of public health interventions for asthma control are
scarce.
Methods: 81 patients with severe asthma (12–75 years) joining a programme in a reference clinic
providing free asthma medication were asked retrospectively about costs and events in the
previous 12 months. During 12 months after joining the programme, information on direct and
indirect costs, asthma control by lung function, symptoms and quality of life were collected. The
information obtained was used to estimate cost-effectiveness of the intervention as compared to
usual public health asthma management. Sensitivity analysis was conducted.
Results: 64 patients concluded the study. During the 12-months follow-up within the programme,
patients had 5 fewer days of hospitalization and 68 fewer visits to emergency/non scheduled
medical visits per year, on average. Asthma control scores improved by 50% and quality of life by
74%. The annual saving in public resources was US$387 per patient. Family annual income increased
US$512, and family costs were reduced by US$733.
Conclusion: A programme for control of severe asthma in a developing country can reduce
morbidity, improve quality of life and save resources from the health system and patients families.
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Background
The prevalence of asthma is increasing in many countries
[1,2]. This trend has been attributed to adoption of west-
ern lifestyle, and it is expected that prevalence of asthma
will continue to increase in developing countries. The
prevalence of uncontrolled severe asthma has also grow-
ing with great economic and social impact for families
and health systems, major health resource utilization, loss
of productivity and deterioration in quality of life.
The primary aim of persistent asthma management is to
gain symptom control, by monitoring clinical manifesta-
tions of airway inflammation and regular use of inhaled
corticosteroids [3,4]. But the proportion of individuals
with persistent asthma reporting use of inhaled corticos-
teroids is low: 41% in Europe, 35% in the U.S.A., 14% in
Asia and only 5% in Brazil [5,6].
Brazil has a high prevalence of asthma, with estimated 10
million people suffering from the disease [9]. In Salvador,
a City located in the State of Bahia, the prevalence of
asthma among adolescents estimated in the first Interna-
tional Study of Asthma and Allergy in Childhood (ISAAC)
survey was 27,1%, one of the highest in the world [10]. In
spite of this high prevalence, the standard strategy for
asthma management in the public health system in Brazil
is limited to treatment of exacerbation with bronchodila-
tors and systemic corticosteroids. The combination of a
high prevalence and the lack of access to secondary pre-
vention through pharmacotherapy in the public health
system, leads to high morbidity and unacceptable mortal-
ity [9]. In 2003, a pilot programme for management and
control of severe asthma started in an outpatient clinic of
Federal University of Bahia School of Medicine. The pro-
gramme is offered by the state health system and includes
specialized care, patient education and free inhaled med-
ication for asthma and rhinitis [11].
Resources for public health actions are always limited,
and therefore it is crucial for policy makers [8], to have
evidence from clinical and economic studies, to define
their priorities and to balance costs and effectiveness of
available alternatives. This is true for both wealthy and
developing countries. We hypothesized that severe
asthma generate so high economic burden on the health
care system and families that an intervention programme
offering the best management for severe asthma would
benefit patients without increasing costs. The study
reported here was a cost-effectiveness analysis of this pro-
gramme for management and control of severe asthma in
Brazil, considering government and family direct and
indirect costs involved in asthma management.
Methods
The Programme for control of asthma and Allergic Rhinitis 
in Bahia (ProAR)
This programme was organized by Federal University of
Bahia Medical School and obtained operational support
from the Unified Health Service (in Salvador, a unified
public health system, comprising the Department of
Health of the City of Salvador, the Department of Health
of the State of Bahia and Brazilian Ministry of Health
[11]). ProAR aims were to reduce symptoms and prevent
exacerbations in severe asthmatics, with an integrated
approach by a team of chest physicians, allergists, pedia-
tricians, nurses, pharmacists, social workers and psychol-
ogists. Asthma education sessions are offered to patients
and family members. Inhaled corticosteroids (budeso-
nide) combined with long acting bronchodilators (for-
moterol) are given with no cost to all patients, as
recommended by Global Initiative for Asthma (GINA)
guidelines [12]. Nasal topical corticosteroids are also
given to those with concomitant chronic rhinitis. ProAR
started recruiting patients with severe asthma in Salvador
in 2003; by October 2006, 1796 patients had been
recruited into the programme.
Participants
Eighty-one patients with severe asthma, from 12 to 75
years old, living in Salvador and its metropolitan area,
were consecutively selected from those attending regularly
the referral clinic for ProAR. To be included in the study,
patients were required to have more than one year of
severe asthma according to the classification by the Global
Initiative for Asthma [12]. Therefore, the patients typically
had continuous asthma symptoms, as well as daily limita-
tion to exercise, frequent exacerbations and night symp-
toms, requiring daily use of a bronchodilator. The
majority reported frequent emergency visits, hospitaliza-
tions, and some had been admitted to intensive care units.
They also had a low forced expiratory volume in one sec-
ond (FEV1) on spirometry. Additionally, patients were
required to have no contraindications for the use of the
inhaled corticosteroids and/or long acting beta 2 agonists
bronchodilators, no concomitant lung disease (as
assessed by history and chest X-Ray); to be non-smokers
or have a smoking history < 10 pack/years and be capable
of giving written informed consent. Recruitment was lim-
ited by convenience to patients admitted to the pro-
gramme between April and September of 2004.
Study design and evaluation procedures
This is a "before and after study" (pre-post study) of 81
patients with severe asthma, managed in ProAR. The
objective was to compare the cost-effectiveness, for fami-
lies and the public health system, of two strategies for
severe asthma management of the same patients: the reg-
ular asthma care available in the Salvador public health
system they used before joining ProAR and that offered by
ProAR. The analysis considered the management of
asthma one year before and one year after admission to
ProAR.
Figure 1 summarizes the chronology of the study proce-
dures. Upon referral to the programme, the selected
patients were invited to participate in this study, to sign an
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informed consent form, and to answer the AQLQ
(Asthma Quality of Life Questionnaire) and the ACQ
(Asthma Control Questionnaire) that are standard instru-
ments to measure asthma control and asthma-specific
quality of life, both of which had previously undergone
linguistic validation to Portuguese and are available elec-
tronically [13-16]. A month later they had their first med-
ical consultation in ProAR, when they were seen by a
specialist and received free medication. Both ACQ and
AQLQ questionnaires were repeated during this visit.
Afterwards, the ACQ and AQLQ questionnaires were
answered every 3 months during the one-year of follow
up. The two initial repeated questionnaire scores one
month apart were taken as the patients' baseline status of
asthma control and quality of life before intervention.
During the initial visit researchers collected economic and
clinical retrospective information regarding asthma treat-
ment in the past 12 months, including patient's and fam-
ily's income, expenses with transportation, doctor's visits,
medications, therapeutical devices and diagnostic tests,
emergency room visits, hospitalizations and intensive
care admissions due to asthma. The same information
was then collected prospectively on monthly visits during
ProAR follow up and intervention for one year, for com-
parison with the previous year. Patients performed lung
function tests to obtain forced vital capacity (FVC), forced
expiratory volume in 1 second (FEV1) and peak expiratory
flow rate (PEF) at baseline, before joining ProAR, and at 6
and 12 months of follow up to objectively evaluate their
asthma control status [17]. The Ethics Committee of
Human Research – School of Medicine of Federal Univer-
sity of Bahia, approved the study.
The economic analysis
In order to compare the cost-effectiveness of treatment of
severe asthma for the two strategies (regular public health
system care and the ProAR), the costs for the public health
system, for ProAR and for the families were estimated
using accounting procedures. All these costs have been
brought up to values at the time of the main analysis (Feb-
ruary 2006) and the necessary depreciation estimated.
Costs were estimated for the public health system and for
ProAR: health related direct costs for each patient, before
and after their inclusion on the programme. The costs of
outpatient care within the year before intervention, com-
prising doctor's visits, medications and diagnostic tests
were calculated based on patient' retrospective informa-
tion and using government official reimbursement values
and pharmaceutical retail price. The costs of hospitaliza-
tion, emergency room visits, and intensive care unit
admissions, both after and before joining ProAR, were
estimated based in Health Department of State of Bahia
databases and public and charity hospitals' financial
department surveys. To estimate the average cost of a day
of hospitalization for a case of asthma we took into
account the average total direct costs with hostelry (staff,
current expenses, equipment and facilities depreciation,
office and medical supplies), the number of total patients
and the proportion of patients with asthma hospitalized
per year, and the costs of specific asthma medication. The
costs of ambulatory health care in ProAR were estimated
as follows: the total annual stable costs with current regu-
lar expenses (administration, water supply and energy
consumption, security, cleaning, maintenance), office
and medical supplies, communications and staff, divided
by the total number of patients admitted, to obtain the
cost per patient/year. The variable costs were estimated by
analyzing individual expenses with diagnosis and treat-
ment.
Family costs- family's direct and indirect costs were esti-
mated by using the Asthma Family's Costs Questionnaire
(AFCQ), which collects information on the costs incurred
by the families due to asthma treatment of a family mem-
ber. This was adapted from a questionnaire previously cre-
ated to estimate family costs of tuberculosis in Brazil [18].
The AFCQ reliability and reproducibility were evaluated
and confirmed in asthma among 30 patients of our pro-
gramme. The AFCQ is available electronically [19] and
detailed results of its validation have been a matter of a
paper that has been submitted to publication. This instru-
ment has 33 questions divided into sets of items: family
income, financial help, transportation expenses, loss of
job, school absence due to asthma, medicines purchase,
other expenses and loss of time waiting or moving to
health services. The questionnaire was applied at baseline,
to quantify expenses over the year before patient's admis-
sion to ProAR, and again at the end of study, to measure
costs to the family during the year of ProAR intervention.
Cost-effectiveness analysis - the analysis was conducted to
compare two treatment strategies for severe asthma. The
first one is the regular treatment offered by the public
health system in Salvador, in which patients received
treatment only to control exacerbations with no regular
inhaled or oral preventive medications or regular follow
Study design and evaluations scheduleFigure 1
Study design and evaluations schedule.
regular management in the 
public health system 
12 months (retrospective) 1
 m
 
13 months prospective observation 
3 m 3 m 3 m 3 m 
V0 V1 V2 V3 V4 V5
V0: self-report on morbidity, AQLQ, ACQ, family costs questionnaire 
V1: self-report on morbidity, AQLQ, ACQ, lung function 
V2: self-report on morbidity, AQLQ, ACQ 
V3: self-report on morbidity, AQLQ, ACQ, lung function 
V4: self-report on morbidity, AQLQ, ACQ 
V5: self-report on morbidity, AQLQ, ACQ, family costs questionnaire, lung function 
12 months programe intervention 
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up. The second approach, in the same patients, after
admission to ProAR and being followed prospectively for
one year receiving multiprofessional regular care, free
inhaled preventive medication and educational sessions.
The effectiveness of the intervention was measured as
"hospitalizations avoided" by the programme. Cost-effec-
tiveness incremental analysis was performed by compar-
ing the costs and health results, dividing the difference in
costs per the difference of health results obtained on each
strategy [20].
Sensitivity analysis – this was carried out to ascertain the
reliability of the cost-effectiveness analysis under varied
assumptions regarding costs of health care. We challenged
our main findings by repeating the cost-effectiveness anal-
ysis while changing the estimated hospitalization cost
from our real life calculus to what was reimbursed to the
State or City Departments from the Ministry of Health,
which was 76% less [21].
Statistical analysis
The sample size was calculated by Stats Direct 7.0 software
considering the estimated ProAR intervention effect of
reducing hospitalizations during one year, as compared to
the year before. Hospitalizations are an important param-
eter to assess asthma control, morbidity and costs [12].
The minimum sample size required to detect as statisti-
cally significant a 50% reduction in costs per patient/year
was 58 patients, for a power of 80%. We increased the
sample to 81 patients in order to compensate for probable
losses of follow up or mortality of patients with such
severe disease.
Data were entered onto a Microsoft Excel® and SPSS 11.5
spreadsheet for statistical analysis. Two tailed tests were
carried out and p values lower than 0.05 considered statis-
tically significant. The categorical variables were reported
as proportions and compared with Chi-square Tests. All
continuous variables were compared by using Wilcoxon
Signed Rank Test [22].
Results
General characteristics of patients
Most patients came from a poor socio economic stratum,
having a median family income of US$ 2,768 per year.
Many worked in the informal labor market and 14 (17%)
were unemployed. They had low educational level: 68%
had less than 5 years of schooling. The majority of
patients were of mixed ethnicity, predominantly African
origin and 68 (83%) were female. This is consistent with
the literature [22]. They had asthma for an average of 26
years and 22% had another associated chronic disease.
The mean age of patients was 45 ± 16 years, and we found
that severe disabling asthma had a major impact in their
economical activities and indirect costs to their family.
Forty one percent of the families reported loss of a job by
patients or their parents, 5% of the patients had retired
early and 6% never worked because of the asthma (Table
1).
Of the 81 patients included, 64 (79%) concluded the
study. In spite of the regular treatment offered, 3 (4%)
patients died during the one year follow up. A total of
fourteen (17%) patients did not complete the study.
These patients had different characteristics from the com-
pliers: they were younger, of a better socioeconomic sta-
tus, had less comorbidity, and better access to private
health care. Some noncompliers reported having left the
programme because of the time spent in the regular visits
answering our questionnaires.
Health aspects
When comparing reported data for the year before regis-
tration in ProAR to the year after joining for the 64
patients that concluded the follow up, we found an
increase in the use of inhaled corticosteroids, in scheduled
specialist visits and spirometries performed and a sub-
stantial reduction in hospitalizations, in intensive care
Table 1: Demographic, clinical and socioeconomic 
characteristics of the patients included (N = 81)
Age (average +/- SD) 45 ± 16
Ethnicity (n/%)
Caucasian 10 (14)
African descendents 64 (86)
Female gender (n/%) 68 (84)
Occupation (n/%)
Employed 29 (35)
Unemployed 14 (17)
Housewife 15 (19)
Retired 12 (15)
Student 11 (14)
City of residence (n/%)
Salvador 76 (94)
Surrounding cities 5 (6)
Education (n/%)
Illiterate 14 (18)
Middle School completed 40 (50)
High School completed 22 (27)
University completed 4 (5)
Private health insurance holders (n/%) 13 (16)
Presence of comorbities (n/%) 17 (22)
Duration of diagnosis of asthma in years 
(average +/- SD)
26 ± 17
Asthma's restrictions of the patient's or 
families activity (n/%)
School absence 9 (11)
Never worked due to asthma 5 (6)
Early retirement due to asthma 4 (5)
Loss of job by the patient or family 33 (41)
Family annual income (US$) (median/
quartiles)
2768 (1912/
4033)
Data from the retrospective phase
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unit admissions and in emergency room visits/unsched-
uled consultations. Lung function improved 47% in PEF
and 10% in FEV1. ACQ scores improved 29% and quality
of life, as measured by mean overall AQLQ, improved
29% (Table 2). In the one-month baseline period
(between V0 and V1, the two visits performed previous to
intervention in ProAR), the AQLQ and ACQ scores
remained the same. After 3 months of medication, the
scores reached significant improvement, and that was
maintained until the end of the one-year follow up
period.
The average duration of interviews was 30 minutes for
AFCQ, 20 minutes for AQLQ and 10 minutes for ACQ.
Nine percent of patients did not perform spirometries
because of functional limitations and 5% did not answer
the AQLQ because of insufficient intellectual ability.
Economic issues
Table 3 shows that, when the 64 patients have controlled
their asthma in ProAR, the increase in preventive treat-
ment costs including regular inhaled medication, lung
function tests, costs of educational and multidisciplinary
staff was largely compensated by a reduction in hospital
costs. This has lead to a total annual economy of US$ 387
to the public health system per patient, and therefore sav-
ings of US$ 24,768 in public health resources for the
cohort of 64 patients. There was also savings for the fam-
ily: the family's annual income increased 18% (US$ 512/
family/year) and the total costs for the families, compris-
ing expenses and loss of income, were reduced by 90%
(US$ 733). The proportion of total family income spent
with asthma treatment decreased from 29% to 2%. This
resulted in a median annual economy of US$ 1,245 per
family, when we consider the increase in income and the
reduction of total costs. There was a reduction of median
time spent with transportation per patient, from 6 hours
to three hours/month (p < 0.01), and in time waiting on
health services due to asthma from 4 hours to 1.7 hours/
month (p = 0.05).
The evaluation of the burden of asthma in this sample of
patients shows that when patients were treated in the
usual public health system low socioeconomic strata fam-
ilies paid for 52% of the costs of severe asthma while the
government paid 48%. This contrasts with patients regis-
tered in ProAR, with the poor families paid for only 17%
of the costs of the management of severe asthma (Figure
2).
Incremental cost-effectiveness analyses demonstrated
that, for each hospitalization avoided there was a saving
of US$ 1,395 for families and government together. The
incremental cost-effectiveness analysis had a negative
result, which means that ProAR strategy saves resources
and decreases morbidity (Table 4).
The sensitivity analysis we have performed by changing
the cost of hospitalizations has demonstrated that, even
considering only the fraction of the public hospitals costs
reimbursed by the federal government, ProAR strategy of
treatment remains more cost-effective than the usual pub-
lic health system (Table 5).
Discussion
This study demonstrated that an intervention programme
that provides regular specialized care to severe asthmatics,
including free pharmaceutical assistance, is more effective
in controlling severe asthma and improving quality of life,
at a much lower cost, than the regular treatment usually
provided in the public health system, in a sample of
underserved population in Salvador – Brazil. The clinic
and economic impact of the strategy of ProAR in treat-
ment of severe asthma was so high for families and public
health system, that a small sample size of patients was suf-
ficient to demonstrate a statistical significant advantage in
favor of the programme.
Salvador has 2,614,840 inhabitants, and 67% of them use
the public health system [24,25]. The results of this study,
providing evidence that the new intervention has a lower
Table 2: Comparison among two strategies for severe asthma treatment concerning health care utilization, quality of life and asthma 
control (n = 64)
year before ProAR year after ProAR
Health care utilization per patient median (quartiles) median (quartiles) p*
Regular specialist visits 0 (0/0) 9 (6/12) < 0.01
Spirometries performed 1 (0/1) 2 (2/2) < 0.01
Emergency/unscheduled visits 36 (6/120) 1 (0/3) < 0.01
Hospitalizations 1 (0/2) 0 (0/0) < 0.01
Quality of life
Total AQLQ score 2 (2/3) 4 (3/6) < 0.01
Asthma control
ACQ scores 4 (3/5) 2 (0.6/3) < 0.01
% of expected FEV1 69 (49/82) 76 (58/84) 0.560
% of expected PEF 45 (34/66) 66 (49/83) < 0.01
* Wilcoxon Signed Rank Test
BMC Public Health 2007, 7:82 http://www.biomedcentral.com/1471-2458/7/82
Page 6 of 8
(page number not for citation purposes)
cost and greater effectiveness than the regular care, is of
major public health importance to other low and middle
income countries [19] and should lead to implementa-
tion of policies that will benefit a large number of patients
[26]. The finding that organized specific programmes for
asthma control can be more cost-effective is new for devel-
oping countries, but this has been shown before for devel-
oped countries: the National Finnish Programme for
Asthma Control for example, has shown that, after 10
years of implementation, it reached significant reduction
in direct costs with hospitalizations, deaths, disability and
early retirement, despite continued growth of asthma's
prevalence [27].
Incremental cost-effectiveness estimates, in which con-
comitant cost and benefit advantages are detected deserve
careful interpretation. Taking this into consideration our
sensitivity analysis was as conservative as possible.
Although we are confident that our results and conclu-
sions are accurate for this setting, more research is needed
on the impact of programmes for control of severe asthma
in other populations of severe asthmatics from low to
middle income countries. Information on costs of severe
asthma to families is scarce [3,27], although many studies
of cost to the public health system have been reported
[28]. The present study provides a better estimate of the
complete economic impact of severe asthma, by including
family and public health service costs. The AFCQ, used for
the first time in this study, was introduced as an easy and
useful tool to estimate family costs. It has shown that the
economic burden of severe asthma was shared equally by
low-income families and government before ProAR. This
suggests that programmes like ProAR will also have major
socio-economic benefit to families of severe asthmatic
patients.
An Australian study estimated the annual family's costs
for treatment of 238 asthmatic children. It found that the
mean annual treatment cost per asthmatic children was
US$ 164 [29]. In the present study, the annual family
costs (US$ 807) are five times higher. Possibly, this differ-
ence is due to the severity of the asthma of our patients
and because we took into consideration indirect costs too.
In California (USA), a study that analyzed annual costs of
asthma according to the severity of disease, found that
costs of severe athma was US$12,813 per patient/year [3].
In the present study, the total annual burden of disease
per severe asthmatic patient, including family and govern-
ment cost, was of US$ 1,557; eight times less than the Cal-
ifornian study. This may reflect a smaller investment in
asthma control and/or reduced costs of treatment in Bra-
zil, when compared with a developed country.
The success of asthma treatment in preventing exacerba-
tions seems to be associated with regular adequate meas-
ures. Patients with scores of ACQ under 1.5 are considered
under control [16] (This is used as the cut off point for
Burden of disease: severe asthma annual median costs per patient, an  proportion paid by government and families, before and after ProAR interventioFigure 2
Burden of disease: severe asthma annual median costs per 
patient, and proportion paid by government and families, 
before and after ProAR intervention.
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Table 3: Comparison among economic parameters of two strategies for control of severe asthma (n = 64)
year before ProAR (US Dollars) year after ProAR (US Dollars)
median (quartile) median (quartile) p*
Government annual costs of treatment per patient
Cost of outpatient treatment 184 (177/192) 359 (240/471) < 0.01
Cost of hospital treatment 590 (78/1330) 0 (0/19) < 0.01
Total annual government costs of treatment 750 (286/1462) 363 (255/481) < 0.01
Family annual costs of treatment and income
Family income 2768 (1912/4033) 3280 (2191/5050) 0.02
Family expenses with asthma (direct cost) 615 (343/1374) 74 (34/275) < 0.01
Proportion of income spent with asthma 29% 2%
Losses for patient and companion (indirect cost) 0 (0/134) 0 (0/0) < 0.01
Total family costs (direct + indirect) 807 (358/1509) 74 (35/281) < 0.01
* Wilcoxon Signed Rank Tests
BMC Public Health 2007, 7:82 http://www.biomedcentral.com/1471-2458/7/82
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clinical trials). Within one year of follow up, patients
treated in ProAR, with asthma of 25 years duration on
average, reduced the ACQ score from four (poorly con-
trolled) to two, which is very close to adequate control.
Lung function measurements (FEV1 and peak flow) were
less responsive to changes in asthma control than ACQ
scores, in this study, which is in agreement with previous
reports.
Severe or uncontrolled asthma causes limitations and has
an impact in physical, social, and emotional well-being of
patients and their families. Its control may result in
remarkable change in quality of life [15]. After ProAR
intervention, patients left a situation of extreme limitation
(AQLQ mean score of 2) to enter a mild/moderate limita-
tion zone (AQLQ mean score of 4) during the one year of
intervention.
The main limitation of our study is that information from
the year before intervention was collected retrospectively
from patient reports. It would not be ethical to have a par-
allel control group of severe asthmatics followed up with-
out access to ProAR, once free preventive inhaled
medication was made available. Therefore, the only way
we could study patients inside and outside the pro-
gramme was comparing their own profile before and after
the intervention. In this study, patients apparently had no
difficulty to recall hospitalizations, emergency room vis-
its, income, financial help, medicine prices, and transpor-
tation expenses. They were able to document their recent
expenses with medicine bringing in boxes and/or drug-
store receipts and some hospitalizations and emergency
visits with medical reports and prescriptions. The presence
of an interviewer might have influenced the patient's
answers. However, this was needed as the majority of
patients had low educational level and some were illiter-
ate. The interviewer was trained to avoid influencing the
answers, and was the same for all patients during all the
study [30].
Conclusion
In conclusion, this study has demonstrated that, in a
developing country, a public health programme aimed to
control severe asthma offering specialized multidiscipli-
nary care in a reference clinic, based on secondary preven-
tion of symptoms and exacerbations with a combination
of inhaled corticosteroid and long acting beta 2 agonist
bronchodilator (given for free), and patient's education, is
Table 5: Sensitivity analysis of the strategies for treatment of 64 severe asthma patients
Strategies Costs (US$) Hospitalizations Health 
Result
Incremental 
Cost (US$)
Cost-effectiveness 
incremental
(C-D) (B-A) (F/E)
Intervention 1
The usual treatment of severe asthma offered by the public health 
system with medication for exacerbations
133,991
(A)
85
(C)
Intervention 2
Treatment of severe asthma offered by ProAR with inhaled 
corticosteroid + long acting bronchodilators
56,256
(B)
1
(D)
84
(E)
-77,735
(F)
-925
Main result: there was an economy of US$ 925 per hospitalization avoided.
The effectiveness of the intervention was measured as "hospitalization avoided" by the programme and the costs are including the families and 
governments costs.
Table 4: Cost-effectiveness incremental analysis of the strategies for treatment of 64 severe asthma patients
Strategies Costs (US$) Hospitalizations Health 
Result
Incremental 
Cost (US$)
Cost-effectiveness 
incremental
(C-D) (B-A) (F/E)
Intervention 1
The usual treatment of severe asthma offered by the public health 
system with medication for exacerbations
173,440
(A)
85
(C)
Intervention 2
Treatment of severe asthma offered by ProAR with inhaled 
corticosteroid + long acting bronchodilator
56,256
(B)
1
(D)
84
(E)
-117,184
(F)
-1,395
Main result: there was an economy of US$ 1,395 per hospitalization avoided.
The effectiveness of the intervention was measured as "hospitalization avoided" by the programme and the costs are including the families and 
governments costs.
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a more cost-effective alternative to manage severe asthma
than the previous regular public health approach of treat-
ing exacerbations only. The reduction in government and
family direct and indirect costs is so remarkable that it
compensates all the costs involved in running the pro-
gramme and supplying effective medicines, with incre-
mental economy to the government and to families'
budgets. And above that it has improved asthma control
and asthma related quality of life. A well-structured pro-
gramme for asthma control, focused in severe cases, can
reduce morbidity, improve quality of life, and decrease
health related costs in middle income countries.
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